Senti Bio Appoints Feng Hsiung to Board of Directors
13 mars 2025 16h01 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Strengthens Leadership Team with Strategic Hires
25 févr. 2025 08h00 HE
|
Senti Biosciences, Inc.
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO,...
Senti Bio Announces Additional $11.5 Million of Financing
06 janv. 2025 09h00 HE
|
Senti Biosciences, Inc.
– Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – ...
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics
16 déc. 2024 08h00 HE
|
Senti Biosciences, Inc.
– Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN...
Senti Biosciences Announces New Employment Inducement Grants
03 déc. 2024 20h00 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene...
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing
02 déc. 2024 07h10 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML
02 déc. 2024 07h02 HE
|
Senti Biosciences, Inc.
– 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – – Dose escalation is continuing with...
Senti Bio Appoints Fran Schulz to Board of Directors
02 déc. 2024 07h00 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing...
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
14 nov. 2024 16h05 HE
|
Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a biotechnology company developing next-generation cell and gene...
Senti Bio to Participate in Upcoming Investor Conferences
03 sept. 2024 08h15 HE
|
Senti Biosciences, Inc.
Senti Bio will participate in two upcoming investor conferences in September.